afatinib + necitumumab

Afatinib + necitumumab is an investigational combination therapy consisting of two agents targeting the epidermal growth factor receptor (EGFR) pathway, evaluated primarily in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have developed resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy. Afatinib is an oral, irreversible small molecule inhibitor of the ErbB family of receptors, including EGFR. Necitumumab is a recombinant human IgG1 monoclonal antibody that binds to EGFR and blocks ligand binding, leading to receptor internalization and degradation. The rationale for combining these agents is dual inhibition of the EGFR pathway through both extracellular blockade (necitumumab) and intracellular kinase inhibition (afatinib). In phase 1 clinical trials, this combination demonstrated acceptable safety but limited efficacy in heavily pretreated patients with acquired resistance to TKIs[1][3][2].